ES2104731T3 - Micobacterium utilizado como adyuvante para antigenos. - Google Patents

Micobacterium utilizado como adyuvante para antigenos.

Info

Publication number
ES2104731T3
ES2104731T3 ES91919563T ES91919563T ES2104731T3 ES 2104731 T3 ES2104731 T3 ES 2104731T3 ES 91919563 T ES91919563 T ES 91919563T ES 91919563 T ES91919563 T ES 91919563T ES 2104731 T3 ES2104731 T3 ES 2104731T3
Authority
ES
Spain
Prior art keywords
antigens
micobacterium
adjuvant
micobacteria
immunoregulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919563T
Other languages
English (en)
Inventor
Graham Arthur William Old Rook
John Stanford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909024282A external-priority patent/GB9024282D0/en
Priority claimed from GB919115410A external-priority patent/GB9115410D0/en
Application filed by University College London filed Critical University College London
Application granted granted Critical
Publication of ES2104731T3 publication Critical patent/ES2104731T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EL METERIAL INMUNOREGULADOR DE UNA MICOBACTERIA DIFERENTE A LA "M. TUBERCULOSIS", ESPECIALMENTE CELULAS MUERTAS DE "M.VACCAE", ES UN COADYUDANTE VENTAJOSOS PARA SU ADMINISTRACION CON ANTIGENOS (INCLUIDOS ALERGENOS).
ES91919563T 1990-11-08 1991-11-08 Micobacterium utilizado como adyuvante para antigenos. Expired - Lifetime ES2104731T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909024282A GB9024282D0 (en) 1990-11-08 1990-11-08 Antigen carrier
GB919115410A GB9115410D0 (en) 1991-07-17 1991-07-17 Antigen carrier

Publications (1)

Publication Number Publication Date
ES2104731T3 true ES2104731T3 (es) 1997-10-16

Family

ID=26297923

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919563T Expired - Lifetime ES2104731T3 (es) 1990-11-08 1991-11-08 Micobacterium utilizado como adyuvante para antigenos.

Country Status (11)

Country Link
US (1) US5599545A (es)
EP (1) EP0556248B1 (es)
JP (1) JPH06501479A (es)
AT (1) ATE154759T1 (es)
AU (1) AU660430B2 (es)
CA (1) CA2095855C (es)
DE (1) DE69126668T2 (es)
DK (1) DK0556248T3 (es)
ES (1) ES2104731T3 (es)
GR (1) GR3024750T3 (es)
WO (1) WO1992008488A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5736146A (en) * 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
AU691797B2 (en) * 1993-01-29 1998-05-28 Vetrepharm, Inc. Immunotherapeutic composition
EP0700445B1 (en) 1993-06-04 2002-01-23 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5725860A (en) * 1994-03-07 1998-03-10 Auckland Uniservices Limited Method for reducing the risk of developing diabetes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5869058A (en) * 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
EP0951289B1 (en) * 1996-12-18 2005-10-26 Stanford Rook Limited Use of mycobacterium vaccae for treating chronic fatigue syndrome
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2284736A1 (en) * 1997-03-28 1998-10-08 Cytoclonal Pharmaceutics, Inc. Mycobacterium recombinant vaccines
AU7154998A (en) * 1997-04-24 1998-11-13 Lovelace Respiratory Research Institute Prevention and treatment of allergic disease by targeted development of protective t-helper lymphocyte immunity
HUP0003601A3 (en) 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6328978B1 (en) * 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
AU2337499A (en) * 1998-01-23 1999-08-09 National Jewish Medical And Research Center Method for treating inflammatory diseases using heat shock proteins
ES2355483T3 (es) 1998-02-20 2011-03-28 University Of Miami Complejo de proteina de choque térmico modificada-péptido antigénico.
US6569436B1 (en) 1998-10-05 2003-05-27 The Malaghan Institute Of Medical Research Method of using a vaccine
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
JP4415200B2 (ja) * 1999-01-29 2010-02-17 大塚製薬株式会社 遅発育性抗酸菌ポリペプチド
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
US20040247622A1 (en) * 1999-06-02 2004-12-09 Genesis Research And Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using Mycobacterium vaccae
AU5926700A (en) * 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
WO2001051081A1 (en) 2000-01-14 2001-07-19 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
PT2133100E (pt) * 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
KR100919266B1 (ko) 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
GB0025694D0 (en) * 2000-10-19 2000-12-06 Univ London Vaccine
US6921534B2 (en) * 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US20030147861A1 (en) * 2001-07-26 2003-08-07 Genesis Research And Development Corporation Limited Compounds and methods for the modulation of immune responses
HK1079705A1 (zh) 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2004026024A2 (en) * 2002-09-20 2004-04-01 The United States Of America As Represented By The Secretary Of Agriculture Vaccine compositions and adjuvant
EP2258441A3 (en) * 2005-09-02 2011-09-21 Intercell USA, Inc. Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (es) * 1971-11-19 1975-02-07 Anvar
NL7308450A (es) * 1972-06-20 1973-12-27
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4930169A (en) * 1988-12-27 1990-06-05 Kenneth Davison Apparatus for patient hydrotherapy and manipulative treatment by a therapist
DE69027112T2 (de) * 1989-01-23 1997-01-09 Auspharm International Ltd 4Th Impfstoffzusammensetzung
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
WO1992008488A1 (en) 1992-05-29
ATE154759T1 (de) 1997-07-15
EP0556248B1 (en) 1997-06-25
CA2095855C (en) 2003-04-29
US5599545A (en) 1997-02-04
DE69126668T2 (de) 1997-10-23
DE69126668D1 (de) 1997-07-31
JPH06501479A (ja) 1994-02-17
EP0556248A1 (en) 1993-08-25
AU660430B2 (en) 1995-06-29
AU8874191A (en) 1992-06-11
DK0556248T3 (da) 1997-10-27
GR3024750T3 (en) 1997-12-31
CA2095855A1 (en) 1992-05-09

Similar Documents

Publication Publication Date Title
DK0556248T3 (da) Mycobacterium som adjuvans til antigener
NO922566L (no) Implantasjonsmateriale som gir naer vaskularisering
FI872917A0 (fi) Farmaceutiska baerare, vilka frigoer aktivaemnet reglerbart.
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
AU6618986A (en) Immunostimulant agents
ES2007720A6 (es) Procedimiento de obtencion de una vacuna a base de flagelo bacterial.
ES2023976B3 (es) Procedimiento para el enriquecimiento de helio.
LV11985A (lv) Noteiktu cistina atvasinajumu farmakologiska izmantosana
ES555005A0 (es) Un procedimiento para preparar una formulacion en emulsion de anfotericina b adecuada para administracion parenteral.
ES2098358T3 (es) Metodo para preparar cristales de interferon alfa-2.
ES2106784T3 (es) Factor de transferencia y metodos de uso.
ES8607020A1 (es) Acidos 1-ciclopropilquinolon-3-carboxilicos
ES2189788T3 (es) Regulacion de las respuestas del sistema inmunitario utilizando citoquinas y antigenos.
ES2056153T3 (es) Expectorante que comprende un derivado hidroxialquilcisteina.
ES2111163T3 (es) Uso de fosfonatos para el tratamiento de la osteoporosis.
NO930203L (no) Polypeptidforbindelser med veksthormonfrigjoerende aktivitet
ES458197A1 (es) Un procedimiento para la preparacion de nuevos peptidoglica-nos.
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES2088431T3 (es) Preparacion biologica y su utilizacion.
ES2103575T3 (es) Procedimiento para la preparacion de 9-(2-hidroxi)-etoximetil-guanina.
ES2028871T3 (es) Un procedimiento para la preparacion de un glicosido de antraciclina. .
SE8206886D0 (sv) Anordning for uppberning av en person
ES2099820T3 (es) Procedimiento para la preparacion de trans-piperidina-2,5-dicarboxilatos.
ES2152315T3 (es) Xamoneline tartrato.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 556248

Country of ref document: ES